TD 1607
Alternative Names: TD-1607Latest Information Update: 28 Apr 2018
At a glance
- Originator Theravance
- Developer Theravance Biopharma
- Class Antibacterials; Cephalosporins; Glycopeptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Gram-positive-infections(In volunteers) in USA (IV)
- 21 Apr 2016 Phase I development is ongoing in USA
- 01 Jul 2014 Theravance completes a phase I trial in Healthy volunteers in in USA (NCT01949103)